Personalized mRNA Vaccine Reduces Melanoma Recurrence Risk by More Than 40%
A Phase 3 clinical trial found that a personalized mRNA vaccine reduced the risk of melanoma recurrence by more than 40%. The vaccine is designed for each patient based on the characteristics of their tumor.
The results suggest that mRNA vaccines may offer a new approach to cancer treatment by directing the immune system against tumor-specific targets. The reported outcome also provides further evidence of the broader potential of mRNA technology in medicine.